Recent Advances, Controversies, and Emerging Trends in MBC
Medical Community, Clinical Research, Obstacles to Better Outcomes, Clinical Trials Process, Novel Treatments, Diagnosis and Treatment Our MBClife Medical Community, Clinical Research, Obstacles to Better Outcomes, Clinical Trials Process, Novel Treatments, Diagnosis and Treatment Our MBClife

Recent Advances, Controversies, and Emerging Trends in MBC

Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.

Read More